Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06947109
PHASE1

A Clinical Study of AK139 in Healthy Subjects

Sponsor: Akeso

View on ClinicalTrials.gov

Summary

This is a phase I clinical study on dose escalation evaluating the safety, tolerability, PK and PD of a single dose of AK139 administered subcutaneously in healthy subjects.

Official title: A Phase I Clinical Study on Dose Escalation Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of AK139 in Healthy Subjects.

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2025-05-06

Completion Date

2026-01-30

Last Updated

2025-04-27

Healthy Volunteers

Yes

Interventions

DRUG

Placebo

Monitor for a minimum of 24 hours to assess whether the safety and tolerability are acceptable according to the investigator.

DRUG

AK111

The study will use dose escalation scheme. Before proceeding to randomize the next group of subjects, the safety data from all subjects in the previous dose group must be reviewed and confirmed.

Locations (1)

Zhejiang Xiaoshan Hospital

Hangzhou, Zhejiang, China